WINTON GROUP Ltd Makes New $748,000 Investment in Illumina, Inc. $ILMN

WINTON GROUP Ltd acquired a new position in Illumina, Inc. (NASDAQ:ILMN) during the third quarter, HoldingsChannel reports. The institutional investor acquired 7,876 shares of the life sciences company’s stock, valued at approximately $748,000.

Several other hedge funds have also recently made changes to their positions in the business. Parkside Financial Bank & Trust raised its holdings in shares of Illumina by 65.7% during the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 115 shares in the last quarter. Quent Capital LLC bought a new stake in Illumina in the third quarter valued at $29,000. Aster Capital Management DIFC Ltd bought a new stake in Illumina in the third quarter valued at $33,000. Mather Group LLC. purchased a new position in Illumina during the 3rd quarter valued at $46,000. Finally, Evelyn Partners Investment Management LLP raised its holdings in Illumina by 4,927.3% in the 2nd quarter. Evelyn Partners Investment Management LLP now owns 553 shares of the life sciences company’s stock worth $49,000 after purchasing an additional 542 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Illumina

In other news, SVP Patricia Leckman sold 2,370 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the transaction, the senior vice president directly owned 16,321 shares in the company, valued at $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ILMN. TD Cowen reaffirmed a “hold” rating on shares of Illumina in a research note on Wednesday, January 7th. JPMorgan Chase & Co. decreased their price target on shares of Illumina from $130.00 to $120.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. Weiss Ratings restated a “hold (c-)” rating on shares of Illumina in a report on Monday, December 29th. Guggenheim raised their price objective on Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, Barclays boosted their target price on shares of Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a report on Monday, December 15th. Six research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $129.69.

Illumina Stock Up 3.1%

Shares of ILMN traded up $3.59 during mid-day trading on Friday, reaching $119.15. The company had a trading volume of 332,891 shares, compared to its average volume of 2,163,131. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The company has a market capitalization of $18.22 billion, a price-to-earnings ratio of 21.86, a price-to-earnings-growth ratio of 2.32 and a beta of 1.45. The firm has a 50-day moving average price of $133.45 and a 200 day moving average price of $119.68. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $155.53.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the company earned $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, sell-side analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.